Vestal Point Capital
$4.3B 13F equity value
99 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Vestal Point Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc | 6,025,000 | $345M | 8.1% |
| NBIX | Neurocrine Biosciences Inc | 1,880,000 | $317M | 7.4% |
| ABVX | Abivax SA | 2,349,443 | $313M | 7.3% |
| UTHR | United Therapeutics Corp | 435,000 | $236M | 5.5% |
| ELVN | Enliven Therapeutics Inc | 4,000,000 | $203M | 4.7% |
| NRIX | Nurix Therapeutics Inc | 8,050,000 | $195M | 4.6% |
| BCAX | Bicara Therapeutics Inc | 5,250,000 | $156M | 3.6% |
| TSHA | Taysha Gene Therapies Inc | 19,415,000 | $132M | 3.1% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1,575,000 | $128M | 3.0% |
| ABT | Abbott Laboratories | 1,400,000 | $127M | 3.0% |
Track Vestal Point Capital's 13F portfolio: $4.3B in reported holdings, 99 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}